I/ONTAK Shows Benefit for CTCL
https://pixabay.com/photos/hospital-infusion-hand-association-834157/

I/ONTAK Shows Benefit for CTCL

In a Phase 3 clinical trial, researchers evaluated I/ONTAK (also known as E7777) as a potential therapeutic option for persistent or recurrent cutaneous T-cell lymphoma (CTCL). According to Targeted Oncology,…

Continue Reading I/ONTAK Shows Benefit for CTCL
Making a Difference: An Interview With Debra Miller on the Founding of CureDuchenne
source: pixabay.com

Making a Difference: An Interview With Debra Miller on the Founding of CureDuchenne

CureDuchenne is one of Patient Worthy's partner organizations. Patient Worthy partners with a variety of rare disease and patient-oriented non-profits in order to collaborate and help promote one another's activities.…

Continue Reading Making a Difference: An Interview With Debra Miller on the Founding of CureDuchenne